NRX Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $99.02M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 17, 2026 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 18, 2025 | After market close | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 21, 2025 | After market close | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 21, 2025 | After market close | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 15, 2024 | After market close | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 15, 2024 | After market close | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | Apr 2, 2024 | Before market open | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | Before market open | – | $-0.07 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 31, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 14, 2022 | Before market open | – | – | – |
Press releases
Announcements NRX Pharmaceuticals filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. Announces Closing of $22.3 Million Public Offering of Common Stock and Including Exercise of the Underwriters ’ Option
Material agreement · Other events · EX-99.2 to Form 8-K
NRx Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
Listing notice · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
Regulation FD disclosure · EX-99.1 to Form 8-K
181 Bay Street, Suite 4200
Regulation FD disclosure · EX-99.2 to Form 8-K
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Inclusion of Cohen & Associates, LLC of Sarasota, FL into the HOPE Network and Appointment of Dr. Rebecca Cohen as HOPE Medical Director
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Selected to Present at the 2025
Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports
Material agreement · Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Granted FDA Fast Track Designation for
Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine
Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
HOPE Therapeutics ™ , Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
Material agreement · Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Advances Relationship with Anson Funds with $8.9 Million Financing, Including Above the Market Equity and Senior Secured Debt
Material agreement · New financial obligation · Unregistered share sale · Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Regains Compliance With Nasdaq Minimum Market Value of Listed Securities Requirement
Executive or director change · Other events · EX-99.1 to Form 8-K
HOPE Therapeutics ™ , Inc. and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announce Signing of Binding Term Sheet for $27 Million in Funding for HOPE Clinic Acquisitions and Pharmaceutical Operations
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
2024 VIRTUAL ANNUAL MEETING OF STOCKHOLDERS
Executive or director change · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Second Quarter and Year to Date 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds
Material agreement · New financial obligation · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2024 Financial Results and Provides Business Update
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Attn: Jonathan C. Javitt and Pat Flynn
Other events · EX-99.1 to Form 8-K
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in
Other events · EX-99.2 to Form 8-K
Inc. Announces Proposed Underwritten Public Offering of Common Stock
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
Material agreement · Unregistered share sale · Other events · EX-99.2 to Form 8-K
NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
NRx Pharmaceuticals Announces Reverse Stock
Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
NRx Pharmaceuticals Announces Results of the
Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
NRx Pharmaceuticals, Inc. Announces Proposed
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K